Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between hiv-infected and uninfected individuals: The age H IV cohort study

Clinical Infectious Diseases

Volumn 59, Issue 12, 2014, Pages 1787-1797

  Schouten, Judith ^a,b   Wit, Ferdinand W ^a,c   Stolte, Ineke G ^c,d   Kootstra, Neeltje A ^e   Van Der Valk, Marc ^c   Geerlings, Suzanne E ^c   Prins, Maria ^c,d   Reiss, Peter ^a,c,f  

^a AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^b Department of Neurology ^*  (United States)

^c Internal Medicine Division of Infectious Diseases Center for Infection and Immunity Amsterdam   (United States)

^d Public Health Service Amsterdam Infectious Diseases Research   (United States)

^e Academic Medical Center   (United States)

^f STICHTING HIV MONITORING   (Netherlands)

Author keywords

aging; comorbidity; HIV infection

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ABACAVIR; C REACTIVE PROTEIN; CD14 ANTIGEN; COCAINE; DIDANOSINE; GLUCOSE; HEMOGLOBIN A1C; RITONAVIR; STAVUDINE; VITAMIN D;

ADULT; AGE; AGE ASSOCIATED NONCOMMUNICABLE COMORBIDITY; ALCOHOL CONSUMPTION; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; BODY MASS; BONE DISEASE; CANNABIS USE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DRUG MEGADOSE; FAMILY HISTORY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEN WHO HAVE SEX WITH MEN; METABOLIC DISORDER; MIXED INFECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SELF REPORT; SEXUAL ORIENTATION; SMOKING; VIRUS LOAD; VITAMIN BLOOD LEVEL; WAIST HIP RATIO; AGED; CARDIOVASCULAR DISEASES; HIV INFECTIONS; MIDDLE AGED; PREVALENCE; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 84924971538     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu701     Document Type: Article

References (48)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14:195-207.
3. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Causespecific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndromenegative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol 2013; 177:116-25.
4. Lohse N, Hansen A-BE, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
5. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-9.
6. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-96.
7. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIVinfected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53:1130-9.
8. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53:1120-6.
9. Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47:542-53.
10. Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci 2014; 69:833-42.
11. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
12. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-55.
13. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 2010; 7:69-76.
14. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39:633-45.
15. Capeau J. Premature aging and premature age-related comorbidities in HIV-infected patients: facts and hypotheses. Clin Infect Dis 2011; 53:1127-9.
16. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012; 55:126-36.
17. Negin J, Wariero J, Cumming RG, Mutuo P, Pronyk PM. High rates of AIDS-related mortality among older adults in rural Kenya. J Acquir Immune Defic Syndr 2010; 55:239-44.
18. High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012; 60(suppl 1):S1-18.
19. Amsterdam Cohort Studies. Available at: http://www.amsterdam cohortstudies.org. Accessed 20 December 2013.
20. HIV Monitoring Foundation. Available at: http://www.hiv-monitoring. nl/english. Accessed 20 December 2013.
21. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans: an AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee. J Clin Hypertens (Greenwich) 2005; 7: 102-9.
22. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35(suppl 1):S64-71.
23. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available at: http://www.goldcopd.org/uploads/users/files/GOLD-Spirometry-2010.pdf. Accessed 20 December 2013.
24. The International Society for Clinical Densitometry (ISCD). Available at: http://www.iscd.org/official-positions. Accessed 20 December 2013.
25. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, Khaltaev N. A reference standard for the description of osteoporosis. Bone 2008; 42:467-75.
26. Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr 2012; 60:351-8.
27. Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007; 45:1593-601.
28. Hansen A-BE, Gerstoft J, Kronborg G, et al. Incidence of low and highenergy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS 2012; 26:285-93.
29. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24:1228-30.
30. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIVinfected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44:1625-31.
31. Rasmussen LD, Engsig FN, Christensen H, et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS 2011; 25:1637-46.
32. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIVinfected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-504.
33. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-12.
34. Seaberg EC, Wiley D, Martínez-Maza O, et al. Cancer incidence in the multicenter aids cohort study before and during the HAART era: 1984 to 2007. Cancer 2010; 116:5507-16.
35. Freiberg MS, Chang C-CH, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614-22.
36. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-90.
37. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-95.
38. Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis 2010; 202:723-33.
39. Luc G, Bard J-M, Juhan-Vague I, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 2003; 23:1255-61.
40. Kuller LH, Tracy R, BellosoW, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
41. Baker J, Huppler Hullsiek K, Singh A, et al. Monocyte activation, but not T cell activation, predicts progression of coronary artery calciumin a contemporary HIV cohort. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3-6 March 2013. Abstract 66LB.
42. Tenorio A, Zheng E, Bosch R, et al. Soluble markers of inflammation and coagulation, but not T cell activation, predict non-AIDS-defining events during suppressive ART. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3-6 March 2013. Abstract 790.
43. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-62.
44. Johnsen S, Dolan SE, Fitch KV, et al. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab 2006; 91:4916-24.
45. Hudon SE, Coffinier C, Michaelis S, Fong LG, Young SG, Hrycyna CA. HIV-protease inhibitors block the enzymatic activity of purified Ste24p. Biochem Biophys Res Commun 2008; 374:365-8.
46. Barrowman J, Wiley PA, Hudon-Miller SE, Hrycyna CA, Michaelis S. Human ZMPSTE24 disease mutations: residual proteolytic activity correlates with disease severity. Hum Mol Genet 2012; 21: 4084-93.
47. Perrin S, Cremer J, Faucher O, et al. HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 'Aging' Study. PLoS One 2012; 7: e53035.
48. Martin J, Volberding P. HIV and premature aging: a field still in its infancy. Ann Intern Med 2010; 153:477-9.